Brilliant Violet 650™ anti-human TNF-α | BioLegend 502937 product information

product summary

company name :

BioLegend

other brands :

Babco, Signet, Sternberger Monoclonals, Senetek, Covance

product type :

antibody

product name :

Brilliant Violet 650™ anti-human TNF-α

catalog :

502937

quantity :

25 tests

price :

242 USD

clonality :

monoclonal

host :

mouse

conjugate :

BV650

clone name :

MAb11

reactivity :

human

application :

immunocytochemistry, flow cytometry

more info or order :

BioLegend product webpage

citations: 22

Published Application/Species/Sample/Dilution	Reference
flow cytometry; human; loading ...; tbl s9	Mordmuller B, Surat G, Lagler H, Chakravarty S, Ishizuka A, Lalremruata A, et al. Sterile protection against human malaria by chemoattenuated PfSPZ vaccine. Nature. 2017;542:445-449 pubmed publisher
	Statzu M, Jin W, Fray E, Wong A, Kumar M, Ferrer E, et al. CD8+ lymphocytes do not impact SIV reservoir establishment under ART. Nat Microbiol. 2023;8:299-308 pubmed publisher
	Nogimori T, Suzuki K, Masuta Y, Washizaki A, Yagoto M, Ikeda M, et al. Functional changes in cytotoxic CD8+ T-cell cross-reactivity against the SARS-CoV-2 Omicron variant after mRNA vaccination. Front Immunol. 2022;13:1081047 pubmed publisher
	Ezeonwumelu I, Garcia Vidal E, Riveira Mu xf1 oz E, Felip E, Guti xe9 rrez Chamorro L, Calba I, et al. Pharmacological Inhibition of IKK to Tackle Latency and Hyperinflammation in Chronic HIV-1 Infection. Int J Mol Sci. 2022;23: pubmed publisher
	Saggau C, Martini G, Rosati E, Meise S, Messner B, Kamps A, et al. The pre-exposure SARS-CoV-2-specific T cell repertoire determines the quality of the immune response to vaccination. Immunity. 2022;55:1924-1939.e5 pubmed publisher
	Sun Y, Zhang J, Tong L, Lü J, Chen T, Wei Q, et al. Protocol for evaluating CD8+ T cell-mediated immunity in latently SHIV-infected rhesus macaques with HIV fusion-inhibitory lipopeptide monotherapy. STAR Protoc. 2022;3:101479 pubmed publisher
	Sharan R, Ganatra S, Bucşan A, Cole J, Singh D, Alvarez X, et al. Antiretroviral therapy timing impacts latent tuberculosis infection reactivation in a Mycobacterium tuberculosis/SIV coinfection model. J Clin Invest. 2022;132: pubmed publisher
	Carre C, Wong G, Narang V, Tan C, Chong J, Chin H, et al. Endoplasmic reticulum stress response and bile acid signatures associate with multi-strain seroresponsiveness during elderly influenza vaccination. iScience. 2021;24:102970 pubmed publisher
	Lozano Ojalvo D, Cámara C, Lopez Granados E, Nozal P, Del Pino Molina L, Bravo Gallego L, et al. Differential effects of the second SARS-CoV-2 mRNA vaccine dose on T cell immunity in naive and COVID-19 recovered individuals. Cell Rep. 2021;36:109570 pubmed publisher
	Nel I, Beaudoin L, Gouda Z, Rousseau C, Soulard P, Rouland M, et al. MAIT cell alterations in adults with recent-onset and long-term type 1 diabetes. Diabetologia. 2021;64:2306-2321 pubmed publisher
	Sahillioğlu A, Toebes M, Apriamashvili G, Gomez R, Schumacher T. CRASH-IT Switch Enables Reversible and Dose-Dependent Control of TCR and CAR T-cell Function. Cancer Immunol Res. 2021;9:999-1007 pubmed publisher
	Dijkman K, Aguilo N, Boot C, Hofman S, Sombroek C, Vervenne R, et al. Pulmonary MTBVAC vaccination induces immune signatures previously correlated with prevention of tuberculosis infection. Cell Rep Med. 2021;2:100187 pubmed publisher
	Vierboom M, Dijkman K, Sombroek C, Hofman S, Boot C, Vervenne R, et al. Stronger induction of trained immunity by mucosal BCG or MTBVAC vaccination compared to standard intradermal vaccination. Cell Rep Med. 2021;2:100185 pubmed publisher
	Wang S, Shen Y, Li J, Liu Y, Cheng L, Wu S, et al. Entecavir-induced interferon-λ1 suppresses type 2 innate lymphoid cells in patients with hepatitis B virus-related liver cirrhosis. J Viral Hepat. 2021;28:795-808 pubmed publisher
	Bacher P, Rosati E, Esser D, Martini G, Saggau C, Schiminsky E, et al. Low-Avidity CD4+ T Cell Responses to SARS-CoV-2 in Unexposed Individuals and Humans with Severe COVID-19. Immunity. 2020;53:1258-1271.e5 pubmed publisher
	Sekine T, Perez Potti A, Rivera Ballesteros O, Stralin K, Gorin J, Olsson A, et al. Robust T Cell Immunity in Convalescent Individuals with Asymptomatic or Mild COVID-19. Cell. 2020;183:158-168.e14 pubmed publisher
	Xu C, Yin Y. Measuring Chimeric Antigen Receptor T Cells (CAR T Cells) Activation by Coupling Intracellular Cytokine Staining with Flow Cytometry. Methods Mol Biol. 2020;2108:159-165 pubmed publisher
	Holzer B, Morgan S, Martini V, Sharma R, Clark B, Chiu C, et al. Immunogenicity and Protective Efficacy of Seasonal Human Live Attenuated Cold-Adapted Influenza Virus Vaccine in Pigs. Front Immunol. 2019;10:2625 pubmed publisher
	Thompson E, Darrah P, Foulds K, Hoffer E, Caffrey Carr A, Norenstedt S, et al. Monocytes Acquire the Ability to Prime Tissue-Resident T Cells via IL-10-Mediated TGF-β Release. Cell Rep. 2019;28:1127-1135.e4 pubmed publisher
	Zhuang X, Long E. CD28 Homolog Is a Strong Activator of Natural Killer Cells for Lysis of B7H7+ Tumor Cells. Cancer Immunol Res. 2019;7:939-951 pubmed publisher
	Korner C, Simoneau C, Schommers P, Granoff M, Ziegler M, Hölzemer A, et al. HIV-1-Mediated Downmodulation of HLA-C Impacts Target Cell Recognition and Antiviral Activity of NK Cells. Cell Host Microbe. 2017;22:111-119.e4 pubmed publisher
	Iwamoto S, Iwai S, Tsujiyama K, Kurahashi C, Takeshita K, Naoe M, et al. TNF-alpha drives human CD14+ monocytes to differentiate into CD70+ dendritic cells evoking Th1 and Th17 responses. J Immunol. 2007;179:1449-57 pubmed

product information

Antigen :

TNF-alpha

Apps. Abbrev. :

ICFC, FC

Cat # :

502937

Clone :

MAb11

Item :

Brilliant Violet 650™ anti-human TNF-α

Isotype :

Mouse IgG1, κ

Other Names :

Tumor necrosis factor-α, Cachectin, Necrosin, Macrophage cytotoxic factor (MCF), Differentiation inducing factor (DIF), TNFSF2

Size :

25 tests

Price (USD) :

242 USD

Reactivity :

Human

Clonality :

Monoclonal

Host :

Mouse

Conjugate/Tag/Label :

BV650

Immunogen :

E. coli -expressed, recombinant human TNF-α

Application Notes :

ELISA or ELISPOT Detection: The biotinylated MAb11 antibody is useful as the detection antibody in a sandwich ELISA or ELISPOT, when used in conjunction with the purified MAb1 antibody (Cat. No. 502802/502804) as the capture antibody.Flow Cytometry^3,5,6,10: The fluorochrome-labeled MAb11 antibody is useful for intracellular and membrane-bound immunofluorescent staining and flow cytometric analysis to identify TNF-a-producing cells within mixed cell populations.Additional reported applications (for the relevant formats) include: neutralization^1,2, immunohistochemical staining of paraformaldehyde-fixed, saponin-treated frozen tissue sections^4 and acetone-fixed frozen tissue sections^8, immunocytochemistry^7, and immunofluorescence^9. The MAb11 antibody can neutralize the bioactivity of natural or recombinant TNF-a.Note: For testing human TNF-a in serum or plasma, BioLegend's ELISA Max™ Sets (Cat. No. 430201 to 430206) are specially developed and recommended. The LEAF™ purified antibody (Endotoxin <0.1 EU/µg, Azide-Free, 0.2 µm filtered) is recommended for neutralization of human TNF-a bioactivity (Cat. No. 502922).The Purified MAb1 antibody is useful in neutralization^2 and as the capture antibody in a sandwich ELISA or ELISPOT assay, when used in conjunction with the biotinylated MAb11 antibody (Cat. No. 502904/502914) as the detecting antibody.Clone MAb11 cross-reacts to Cat^11;

more info or order :

BioLegend product webpage